Modul 1

IBD Training Academy

Module 1

Module 1 Review

From mechanism of disease (MoD) to mechanism of action (MoA)

Welcome to the first module of the IBD Training Academy, hosted by Dr Flavio Caprioli and Professor Stefan Schreiber. Module 1 will explore the rationale for different treatment targets in IBD and patient populations who may benefit most from different treatment classes.

Learning objectives

Summarise the key drivers of pathophysiology in IBD and describe how these are targeted by available and investigational treatments
Describe the unmet needs associated with current methods of targeting inflammation and how this varies between class and treatment
Explain how differences in MoA may translate to differences in clinically relevant features (e.g. safety and efficacy, immunogenicity, drug–drug interactions)
Discuss optimum use of biomarkers in clinical practice and how this may change in the future

eLearning

Please complete the eLearning for this module in your own time, accessible through the window below. Don’t forget to take the quiz at the end to assess your learning. To access the eLearning element of this module, please select normal view and then click enter.

Expert
webinar

Making sense of MoA in treatment decision-making

The module 1 'Making sense of MoA in treatment decision-making' expert webinar led by Professor Raja Atreya occurred live on Thursday 5th May 2022 at 15:00-16:00 CEST. If you missed this meeting, please watch the video below. If you have any questions please do reach out to us using the contact details below.

Mentorship

sessions

Mentorship sessions

The mentorship sessions in the module have now passed. Should you have any questions for the module owners or indeed any of our expert faculty, please let us know on IBDtrainingacademy@openhealthgroup.com and we will for ward your questions and contact details to them directly.